Hearing About Breakthroughs Made in Hematologic Malignancies in Boston

Author(s):

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute.

We recently traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute. The meeting covered frontline approaches and sequencing challenges in multiple myeloma, key advances in mantle cell lymphoma, and novel agents in chronic lymphocytic leukemia. Experts also highlighted progress made with CAR T-cell therapy in pediatric acute lymphoblastic leukemia, TKI discontinuation in patients with chronic myeloid leukemia, options for benign hematologic disorders, and headway made in acute myeloid leukemia.